Long-term response in primary renal cancer to sequential antiangiogenic therapy

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages

  Vogelzang, Nicholas J ^a   Samlowski, Wolfram ^a   Weissman, Alan ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 386; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; AXITINIB; PAZOPANIB; PERIFOSINE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; PHOSPHORYLCHOLINE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; BACKACHE; CANCER CHEMOTHERAPY; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; COUGHING; DYSPNEA; FEMALE; HUMAN; INFERIOR CAVA VEIN; INTUSSUSCEPTION; KIDNEY CANCER; KIDNEY CARCINOMA; LETTER; LONG TERM CARE; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; SMALL INTESTINE OBSTRUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT REDUCTION; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; TIME;

ANGIOGENESIS INHIBITORS; BENZENESULFONATES; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PHOSPHORYLCHOLINE; PYRIDINES; PYRROLES; TIME FACTORS;

EID: 70349331487     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.4021     Document Type: Letter

References (11)

1. Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 345:1655-1659, 2001
2. Mickisch GH, Garin A, van Poppel H, et al: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: A randomised trial. Lancet 358:966-970, 2001
3. Samlowski WE, Wong B, Vogelzang NJ: Management of renal cancer in the tyrosine kinase inhibitor era: A view from 3 years on. BJU Int 102:162-165, 2008
4. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al: Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 14:2431-2436, 2008
5. Shuch B, Riggs SB, Larochelle JC, et al: Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int 102:692-696, 2008
6. Amin C, Wallen E, Pruthi RS, et al: Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72:864-868, 2008
7. Jonasch E, Tannir NM: Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14:315-319, 2008
8. Rathmell KW, Cowey C, Amin C, et al: A pilot study of neoadjuvant sorafenib for the treatment of stage T2 or higher renal cell carcinoma. American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, Orlando, FL, February 26-28, 2009 (abstr 315)
9. Vogelzang NJ, Hutson TE, Samlowski W, et al: Phase II study of perifosine in metastatic RCC (clear and non-clear) progressing after one prior therapy (Rx) with a VEGF receptor inhibitor. American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, Orlando, FL, February 26-28, 2009 (abstr 302)
10. Shuch B, Said J, La Rochelle JC, et al: Cytoreductive nephrectomy for patients with advanced kidney cancer and sarcomatoid histology: Is up-front resection indicated, avoidable, and is there an alternative? American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, Orlando, FL, February 26-28, 2009 (abstr 282)
11. Barbastefano J, Garcia JA, Elson P, et al: Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, Orlando, FL, February 26-28, 2009 (abstr 280)